Q
39.10
1.05 (2.76%)
| Previous Close | 38.05 |
| Open | 38.51 |
| Volume | 418,992 |
| Avg. Volume (3M) | 687,271 |
| Market Cap | 2,628,903,936 |
| Price / Earnings (Forward) | 14.39 |
| Price / Sales | 0.860 |
| Price / Book | 0.760 |
| 52 Weeks Range | |
| Earnings Date | 7 Nov 2024 |
| Profit Margin | -66.25% |
| Operating Margin (TTM) | 7.12% |
| Diluted EPS (TTM) | -27.81 |
| Quarterly Revenue Growth (YOY) | -2.30% |
| Total Debt/Equity (MRQ) | 87.23% |
| Current Ratio (MRQ) | 1.38 |
| Operating Cash Flow (TTM) | 99.70 M |
| Levered Free Cash Flow (TTM) | 158.72 M |
| Return on Assets (TTM) | 1.04% |
| Return on Equity (TTM) | -45.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | QuidelOrtho Corporation | Bearish | Bearish |
Stockmoo Score
0.4
| Analyst Consensus | 1.0 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.40 |
|
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 1.46% |
| % Held by Institutions | 108.55% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 57.00 (Craig-Hallum, 45.78%) | Buy |
| Median | 53.50 (36.83%) | |
| Low | 50.00 (UBS, 27.88%) | Hold |
| Average | 53.50 (36.83%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 45.37 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 19 Sep 2024 | 50.00 (27.88%) | Hold | 46.23 |
| Craig-Hallum | 05 Sep 2024 | 57.00 (45.78%) | Buy | 44.50 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HODGES MICHELLE A. | 43.75 | 43.75 | 2,553 | 111,694 |
| Aggregate Net Quantity | 2,553 | |||
| Aggregate Net Value ($) | 111,694 | |||
| Aggregate Avg. Buy ($) | 43.75 | |||
| Aggregate Avg. Sell ($) | 43.75 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HODGES MICHELLE A. | Officer | 08 Nov 2024 | Acquired (+) | 3,970 | 43.75 | 173,688 |
| HODGES MICHELLE A. | Officer | 08 Nov 2024 | Disposed (-) | 1,417 | 43.75 | 61,994 |
| Date | Type | Details |
|---|---|---|
| 19 Nov 2024 | Announcement | QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group |
| 19 Nov 2024 | Announcement | QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group |
| 07 Nov 2024 | Announcement | QuidelOrtho Reports Third Quarter 2024 Financial Results |
| 28 Oct 2024 | Announcement | QuidelOrtho to Participate in Three Upcoming Investor Conferences |
| 17 Oct 2024 | Announcement | QuidelOrtho to Report Third Quarter 2024 Financial Results |
| 09 Oct 2024 | Announcement | QuidelOrtho Announces New R&D Executive Leader |
| 10 Sep 2024 | Announcement | QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer |
| 29 Aug 2024 | Announcement | VITROS® Syphilis Assay Now Available on VITROS 3600 Immunodiagnostic System, VITROS 5600 and VITROS XT 7600 Integrated Systems in the U.S. |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |